タンパク質ホメオスタシスとレニン・アニオテンシン系を改造することによって,カルフィルゾミブ特異的なβ5 / β2プロテアソーム阻害が心臓毒性を誘発する
Max Mendez-Lopez1, Andrej Besse1,2, Christian Zuppinger3
1Laboratory of Experimental Oncology, Division Oncology and Hematology, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
iScience
|September 2, 2025
まとめ
多発性骨髄腫に対するカルフィルゾミブ治療は,タンパク質の安定性と代謝に影響を及ぼし,心臓細胞の機能を損なう. カルフィルゾミブ誘発性心臓毒性の予防には,併用療法が有望であることが示されています.
科学分野:
- 心臓病科
- 腫瘍学
- 分子生物学
背景:
- 多発性骨髄腫 (MM) の治療は,プロテアソーム阻害剤であるカルフィルゾミブと,ボルテゾミブと比較して,心血管に関する有害事象の増加と関連しています.
- MM患者におけるカーフィルゾミブ誘発の心臓毒性の正確なメカニズムは完全に理解されていません.
研究 の 目的:
- 多発性骨髄腫におけるカルフィルゾミブ誘発性心臓毒性の基礎となる分子メカニズムを解明する.
- これらの心血管の副作用を軽減する潜在的な治療戦略を特定する.
主な方法:
- カーフィルゾミブが心筋細胞に与える影響を調査するために,偏りのないマルチオミックスのアプローチ (in vitroおよびin vivo) を採用した.
- タンパク質の収縮性,細胞翻訳,レチノール代謝,およびアンジオテンシンAに関する発見を確認するために,in vitro検証を行った.
- オールトランスレチノ酸とアンジオテンシンII型1受容体阻害剤の有効性をテストした.
主要な成果:
- カーフィルゾミブ治療は,心筋細胞の収縮性を著しく低下させる.
- 主な影響を受ける経路には,タンパク質の収縮性,細胞翻訳,レチノールの酸化代謝,およびアンジオテンシンAレベルが含まれます.
- 全トランスレチノ酸とアンジオテンシンII受容体阻害剤の併用は,ヒトとマウスの両方のモデルで,カルフィルゾミブ誘発の心臓毒性に対して保護されます.
結論:
- タンパク質と代謝失調を伴うカルフィルゾミブ心臓毒性の新しいメカニズムが特定されました.
- このメカニズムは,カルフィルゾミブで治療されたMM患者における心血管疾患の臨床観察と一致しています.
- これらの経路をターゲットにすることで,カルフィルゾミブ関連の心臓毒性を管理するための新しい治療方法が提供される可能性があります.
さらに関連する動画
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
1.9K
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
612
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
27
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
27
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
01:11Renal Failure: Dose Adjustments
152
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
152